In Vitro and In Vivo Antileishmanial Activities of Pistacia vera Essential Oil (original) (raw)
Planta Med 2016; 82(04): 279-284
DOI: 10.1055/s-0035-1558209
Biological and Pharmacological Activity
Original Papers
Georg Thieme Verlag KG Stuttgart · New York
Hossein Mahmoudvand
1Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
2Department of Medical Parasitology and Mycology, Lorestan University of Medical Sciences, Khorramabad, Iran
Ebrahim Saedi Dezaki
3Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran
,
Behrouz Ezatpour
1Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
,
Iraj Sharifi
3Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran
,
Farnaz Kheirandish
2Department of Medical Parasitology and Mycology, Lorestan University of Medical Sciences, Khorramabad, Iran
,
Marzieh Rashidipour
4Young Researchers and Elite Club, Islamic Azad University, Khorramabad Branch, Khorramabad, Iran
Further Information
Publication History
received 23 October 2014
revised 29 September 2015
accepted 05 October 2015
Publication Date:
01 February 2016 (online)
Abstract
This study aims to evaluate the in vitro and in vivo antileishmanial activities of Pistacia vera essential oil and compare their efficacy with a reference drug, meglumine antimoniate (Glucantime®). This essential oil (0–100 µg/mL) was evaluated in vitro against the intracellular amastigote forms of Leishmania tropica (MHOM/IR/2002/Mash2) and then tested on cutaneous leishmaniasis of male BALB/c mice by Leishmania major (MRHO/IR/75/ER). In the in vitro assay, it could be observed that P. vera essential oil significantly (p < 0.05) inhibited the growth rate of amastigote forms (IC50 of 21.3 ± 2.1 µg/mL) in a dose-dependent response compared with the control drug. Meglumine antimoniate also demonstrated antileishmanial effects with an IC50 value of 44.6 ± 2.5 µg/mL for this clinical stage. In the in vivo assay, the results indicated that 30 mg/mL of the essential oil had potent suppression effects on cutaneous leishmaniasis in BALB/c mice (87.5 % recovery), while 10 and 20 mg/mL of the essential oil represented the suppression effects as weak to intermediate. The mean diameter of the lesions decreased about 0.11 and 0.27 cm after the treatment of the subgroups with the essential oil concentrations of 10 and 20 mg/mL, respectively. In contrast, in the subgroup treated with the essential oil concentration of 30 mg/mL, the mean diameter of the lesions decreased about 0.56 cm. In the control subgroups, the mean diameter of the lesions increased to 1.01 cm. The main components of P. vera essential oil were limonene (26.21 %), α-pinene (18.07 %), and α-thujene (9.31 %). It was also found that P. vera essential oil had no significant cytotoxic effect on J774 cells. The present study found that P. vera essential oil showed considerable in vitro and in vivo effectiveness against L. tropica and L. major compared to the reference drug. These findings also provided the scientific evidence that natural plants could be used in traditional medicine for the prevention and treatment of cutaneous leishmaniasis.
Key words
Pistacia vera - Anacardiaceae - essential oil - cutaneous leishmaniasis
References
- 1 World Health Organization. Control of the leishmaniasis. Geneva: WHO (Technical Report Series); 2010. 949. 5-12
- 2 Mahmoudvand H, Shakibaie M, Tavakoli R, Jahanbakhsh S, Sharifi I. In vitro study of leishmanicidal activity of biogenic selenium nanoparticles against Iranian isolate of sensitive and glucan-time-resistant Leishmania tropica . Iran J Parasitol 2014; 9: 452-460
- 3 Santos DO, Coutinho CE, Madeira MF, Bottino CG, Vieira RT, Nascimento SB. Leishmaniasis treatment – a challenge that remains: a review. Parasitol Res 2004; 103: 1-10
- 4 Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19: 11-26
- 5 Berman J. Clinical status of agents being developed for leishmaniasis. Expert Opin Investig Drugs 2005; 14: 1337-1346
- 6 Rocha LG, Almeida JR, Macedo RO, Barbosa-Filho JM. A review of natural products with antileishmanial activity. Phytomedicine 2005; 12: 514-535
- 7 Bozorgi M, Memariani Z, Mobli M, Salehi Surmaghi MH, Shams-Ardekani MR, Rahimi R. Five Pistacia species (P. vera, P. atlantica, P. terebinthus, P. khinjuk, and P. lentiscus): a review of their traditional uses, phytochemistry, and pharmacology. ScientificWorldJournal 2013; 15: 1-33
- 8 Mozaffarian V. Trees and shrubs of Iran. Tehran, Iran: Farhang Moaser; 2005
- 9 Hosseinzadeh H, Behravan E, Soleimani M. Antinociceptive and anti-inflammatory effects of Pistacia vera leaf extract in mice. Iran J Pharm Res 2011; 10: 821-828
- 10 Dedoussis GVZ, Kaliora AC, Psarras S, Chiou A, Mylona A, Papadapoulos NG, Andrikopoulos NK. Antiatherogenic effect of Pistacia lentiscus via GSH restoration and down regulation of CD36 mRNA expression. Atherosclerosis 2004; 174: 293-303
- 11 Hamdan II, Afifi FU. Studies on the in vitro and in vivo hypoglycemic activities of some medicinal plants used in treatment of diabetes in Jordanian traditional medicine. J Ethnopharmacol 2004; 93: 117-121
- 12 Orhan I, Aslan M, Sener B, Kaiser M, Tasdemir D. In-vitro antiprotozoal activity of the lipophilic extracts of different parts of Turkish Pistacia vera L. Phytomedicine 2006; 13: 735-739
- 13 Ozçelik B, Aslan M, Orhan I, Karaoglu T. Antibacterial, antifungal, and antiviral activities of the lipophylic extracts of Pistacia vera . Microbiol Res 2005; 160: 159-164
- 14 Tsokou A, Georgopoulou K, Melliou E, Magiatis P, Tsitsa E. Composition and enantiomeric analysis of the essential oil of the fruits and the leaves of Pistacia vera from Greece. Molecules 2007; 12: 1233-1239
- 15 Alma MH, Nitz S, Kollmannsberger H, Digrak M, Efe FT, Yilmaz N. Chemical composition and antimicrobial activity of the essential oils from the gum of Turkish pistachio (Pistacia vera L.). J Agric Food Chem 2004; 52: 3911-3914
- 16 Cosa P, Vlietinck AJ, Berghe DV, Mae L. Anti-infective potential of natural products: how to develop a stronger in vitro ‘proof-of-concept’. J Ethnopharmacol 2006; 106: 290-302
- 17 Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev 1992; 12: 564-582
- 18 McCutcheon AR, Ellis SM, Hancock REW, Tower GNH. Antibiotic screening of medicinal plants of the British Columbian native peoples. J Ethnopharmacol 1992; 37: 213-223
- 19 de Melo JO, Bitencourt TA, Fachin AL, Cruz EM, de Jesus HC, Alves PB. Antidermatophytic and antileishmanial activities of essential oils from Lippia gracilis Schauer genotypes. Acta Trop 2013; 128: 110-115
- 20 Pearson RA, Manian A, Hall D, Harcus JL, Hewlett L. Antileishmanial activity of chlorpromazine. Antimicrob Agents Chemother 1984; 25: 571-574
- 21 Mahmoudvand H, Sepahvand A, Jahanbakhsh S, Ezatpour B, Ayatollahi Mousavi SA. Evaluation of antifungal activities of the essential oil and various extracts of Nigella sativa and its main component, thymoquinone against pathogenic dermatophyte strains. J Mycol Med 2014; 24: 155-161
- 22 Monzote L, García M, Pastor J, Gil L, Scull R, Maes L, Cos P, Gille L. Essential oil from Chenopodium ambrosioides and main components: activity against Leishmania, their mitochondria and other microorganisms. Exp Parasitol 2014; 136: 20-26
- 23 Sikkema J, De Bont DA, Poolman B. Mechanisms of membrane toxicity of hydrocarbons. Microbiol Mol Biol Rev 1995; 59: 201-222
- 24 Mahmoudvand H, Kheirandish F, Ghasemi Kia M, Tavakoli Kareshk A, Yarahmadi M. Chemical composition, protoscolicidal effects and acute toxicity of Pistacia atlantica Desf. fruit extract. Nat Prod Res 2015; 7: 1-4
- 25 Cristani M, DʼArrigo M, Mandalari G, Castelli F, Sarpietro MG, Micieli D, Venuti V, Bisignano G, Saija A, Trombetta D. Interaction of four monoterpenes contained in essential oils with model membranes: implications for their antibacterial activity. J Agric Food Chem 2007; 55: 6300-6308
- 26 Weniger B, Robledo S, Arango GJ, Deharo E, Arango R, Munoz V. Antiprotozoal activities of Colombian plants. J Ethnopharmacol 2001; 78: 193-200
- 27 Mahmoudvand H, Ezzatkhah F, Sharififar F, Sharifi I, Dezaki ES. Antileishmanial and cytotoxic effects of essential oil and methanol extract of Myrtus communis L. Korean J Parasitol 2015; 53: 21-27
- 28 Adams RP. Identification of essential oil components by gas chromatography/mass spectroscopy. Carol Stream, IL: Allured Publishing Corporation; 2004
- 29 Mahmoudvand H, Tavakoli R, Sharififar F, Minaie K, Ezatpour B, Jahanbakhsh S, Sharifi I. Leishmanicidal and cytotoxic activities of Nigella sativa and its active principle, thymoquinone. Pharm Biol 2014; 4: 1-6
- 30 Ezatpour B, Saedi Dezaki E, Mahmoudvand H, Azadpour M, Ezzatkhah F. In vitro and in vivo antileishmanial effects of Pistacia khinjuk against Leishmania tropica and Leishmania major . Evid Based Complement Alternat Med 2015; 2015: 149707
- 31 Mahmoudvand H, Sharififar F, Sharifi I, Ezatpour B, Fasihi Harandi M, Makki MS, Jahanbakhsh S. In vitro inhibitory effect of Berberis vulgaris (Berberidaceae) and its main component, berberine against different Leishmania species. Iran J Parasitol 2014; 9: 28-36
- 32 OECD Guidelines for the Testing of Chemicals. Repeated Dose Dermal Toxicity: 21/28-day Study. OECD Guidelines for the Testing of Chemicals 1981; 410: 1-8
- 33 Salehabadi AR, Karamian M, Motevalli Haghi F, Namaei MH. Effect of root bark extract of Berberis vulgaris L. on Leishmania major on BALB/c mice. Parasitol Res 2014; 113: 953-957
- 34 Taran M, Mohebali M, Esmaeli J. In vivo efficacy of gum obtained Pistacia atlantica in experimental treatment of cutaneous leishmaniasis. Iran J Public Health 2010; 39: 36-41